Recombinant human MIF (rhMIF) was prepared as described elsewhere [24 (link)] (endotoxin content  < 0.1 EU/mL). MIF antagonist MIF098 [3-(3-hydroxybenzyl)-5-methylbenzooxazol-2-one] was dissolved in DMSO at a concentration of 149 µM [25 (link)]. The neutralizing anti-MIF monoclonal antibody (clone NIHlllD.9) was obtained from ascites after purification using protein A/G spin column and resuspended at 5.15 mg/mL [26 (link),27 (link)]. The cytokine neutralizing antibodies anti-IL-6 and anti-IL-1β (BioLegend, San Diego, CA, USA) were obtained.
Free full text: Click here